期刊
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT
卷 10, 期 9, 页码 1044-1053出版社
WILEY
DOI: 10.1002/cpdd.967
关键词
mobocertinib; drug-drug interaction; inhibition; induction; non-small cell lung cancer
资金
- Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts
- Takeda Pharmaceutical Company Limited
Mobocertinib, an oral tyrosine kinase inhibitor under investigation, was studied for its pharmacokinetics when co-administered with the strong CYP3A4 inhibitor itraconazole and inducer rifampin. Results showed that itraconazole increased the plasma concentration of Mobocertinib significantly, while rifampin decreased it. This suggests caution is needed when combining Mobocertinib with CYP3A inhibitors or inducers in clinical trials.
Mobocertinib (TAK-788) is an investigational oral tyrosine kinase inhibitor targeting epidermal growth factor receptor and human epidermal growth factor 2. A phase 1 open-label, 2-period, fixed-sequence, 2-part study (NCT03928327) characterized effects of a strong CYP3A4 inhibitor (itraconazole) and inducer (rifampin) on the pharmacokinetics (PK) of mobocertinib and its active metabolites, AP32960 and AP32914. Healthy volunteers (n = 12 per part) received a single dose of mobocertinib alone (20 mg, part 1; 160 mg, part 2) and with multiple doses of itraconazole 200 mg once daily (part 1) or rifampin 600 mg once daily (part 2). Coadministration of itraconazole with mobocertinib increased the combined molar area under the plasma concentration-time curve from time 0 to infinity (AUC(0-infinity)) of mobocertinib, AP32960, and AP32914 by 527% (geometric least-squares mean [LSM] ratio, 6.27; 90% confidence interval [CI], 5.20-7.56). Coadministration of rifampin with mobocertinib decreased the combined molar AUC(0-infinity) of mobocertinib, AP32960, and AP32914 by 95% (geometric LSM ratio, 0.05; 90%CI, 0.04-0.07). Based on these results, the strong CYP3A inhibitor itraconazole and inducer rifampin significantly influenced the PK of mobocertinib and its active metabolites. Coadministration of mobocertinib with moderate and strong CYP3A inhibitors or inducers is not recommended in ongoing clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据